Engages in the developing and manufacturing of monoclonal antibody therapeutics
Industry Biotechnology
A.I.dvisor indicates that over the last year, CDMO has been loosely correlated with BEAM. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CDMO jumps, then BEAM could also see price increases.
Ticker / NAME | Correlation To CDMO | 1D Price Change % | ||
---|---|---|---|---|
CDMO | 100% | -7.69% | ||
BEAM - CDMO | 42% Loosely correlated | -8.55% | ||
RXRX - CDMO | 38% Loosely correlated | -16.62% | ||
ADPT - CDMO | 37% Loosely correlated | -4.47% | ||
OABI - CDMO | 37% Loosely correlated | -1.43% | ||
DNLI - CDMO | 36% Loosely correlated | +2.78% | ||
More |
Ticker / NAME | Correlation To CDMO | 1D Price Change % |
---|---|---|
CDMO | 100% | -7.69% |
monoclonal theme (2 stocks) | 41% Loosely correlated | +3.35% |
medical service theme (156 stocks) | 38% Loosely correlated | +0.31% |
medical research theme (128 stocks) | 37% Loosely correlated | +0.46% |